JP2022153418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022153418A5 JP2022153418A5 JP2022108815A JP2022108815A JP2022153418A5 JP 2022153418 A5 JP2022153418 A5 JP 2022153418A5 JP 2022108815 A JP2022108815 A JP 2022108815A JP 2022108815 A JP2022108815 A JP 2022108815A JP 2022153418 A5 JP2022153418 A5 JP 2022153418A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- hvegf
- binding fragment
- antigen
- expression cassette
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024152809A JP2025000642A (ja) | 2016-04-15 | 2024-09-05 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323285P | 2016-04-15 | 2016-04-15 | |
| US62/323,285 | 2016-04-15 | ||
| US201762442802P | 2017-01-05 | 2017-01-05 | |
| US62/442,802 | 2017-01-05 | ||
| US201762450438P | 2017-01-25 | 2017-01-25 | |
| US62/450,438 | 2017-01-25 | ||
| US201762460428P | 2017-02-17 | 2017-02-17 | |
| US62/460,428 | 2017-02-17 | ||
| JP2019505138A JP2019515027A (ja) | 2016-04-15 | 2017-04-14 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| PCT/US2017/027650 WO2017181021A1 (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505138A Division JP2019515027A (ja) | 2016-04-15 | 2017-04-14 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024152809A Division JP2025000642A (ja) | 2016-04-15 | 2024-09-05 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022153418A JP2022153418A (ja) | 2022-10-12 |
| JP2022153418A5 true JP2022153418A5 (OSRAM) | 2023-02-14 |
Family
ID=60041925
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505138A Pending JP2019515027A (ja) | 2016-04-15 | 2017-04-14 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2022108815A Pending JP2022153418A (ja) | 2016-04-15 | 2022-07-06 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2024152809A Pending JP2025000642A (ja) | 2016-04-15 | 2024-09-05 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505138A Pending JP2019515027A (ja) | 2016-04-15 | 2017-04-14 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024152809A Pending JP2025000642A (ja) | 2016-04-15 | 2024-09-05 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20190127455A1 (OSRAM) |
| EP (1) | EP3442577A4 (OSRAM) |
| JP (3) | JP2019515027A (OSRAM) |
| KR (2) | KR20240005973A (OSRAM) |
| AU (2) | AU2017250797A1 (OSRAM) |
| CA (1) | CA3019665A1 (OSRAM) |
| IL (1) | IL262277A (OSRAM) |
| SG (2) | SG11201808440YA (OSRAM) |
| WO (1) | WO2017181021A1 (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| WO2017180936A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| CA3076905A1 (en) * | 2017-09-27 | 2019-04-04 | The Johns Hopkins University | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| BR112020012336A2 (pt) * | 2017-12-19 | 2021-03-30 | Akouos, Inc. | Administração de anticorpos terapêuticos mediada por aav para o ouvido interno |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| US12558434B2 (en) * | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| IL279131B2 (en) * | 2018-06-28 | 2025-06-01 | Univ North Carolina Chapel Hill | Optimized cln5 genes and expression cassettes and their use |
| EP4063510A1 (en) * | 2018-11-07 | 2022-09-28 | Akouos, Inc. | Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear |
| MX2021011889A (es) | 2019-04-03 | 2021-10-26 | Regenxbio Inc | Tratamiento genico para patologias oculares. |
| TW202106708A (zh) * | 2019-04-24 | 2021-02-16 | 美商銳進科斯生物股份有限公司 | 全人類轉譯後修飾之抗體治療劑 |
| US20220305098A1 (en) * | 2019-08-22 | 2022-09-29 | The Regents Of The University Of California | Ube3a for the treatment of angelman syndrome |
| BR112022003811A2 (pt) * | 2019-08-26 | 2022-11-16 | Regenxbio Inc | Tratamento de retinopatia diabética com fab anti vegf totalmente humano modificado pós tradução |
| CN114728049A (zh) | 2019-10-07 | 2022-07-08 | 再生生物股份有限公司 | 腺相关病毒载体药物组合物和方法 |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN113952474A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| IL301947A (en) | 2020-10-07 | 2023-06-01 | Regenxbio Inc | Formulations for suprachoroidal administration such as gel formulations |
| CA3198368A1 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Formulations for suprachoroidal administration such as formulations with aggregate formation |
| US20230364206A1 (en) | 2020-10-07 | 2023-11-16 | Regenxbio Inc. | Gene therapy for ocular manifestations of cln2 disease |
| AU2021358048A1 (en) | 2020-10-07 | 2023-05-25 | Regenxbio Inc. | Formulations for suprachoroidal administration such as high viscosity formulations |
| JP2023547832A (ja) * | 2020-10-28 | 2023-11-14 | リジェネックスバイオ インコーポレイテッド | 眼の適応症に対するベクター化抗ＴＮＦ－α抗体 |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| WO2022129609A2 (en) * | 2020-12-18 | 2022-06-23 | Ac Immune Sa | Antibody delivery |
| EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| WO2022206843A1 (en) * | 2021-03-31 | 2022-10-06 | Wuxi Biologics (Shanghai) Co., Ltd. | A bispecific anti-pd-l1/vegf antibody and uses thereof |
| EP4493596A4 (en) * | 2022-03-17 | 2026-04-01 | Adverum Biotechnologies Inc | Antibody Cassettes of Constituent 3 Anti-Complement, Vectorization and Therapeutic Application |
| CA3247507A1 (en) | 2022-04-06 | 2023-10-12 | Regenxbio Inc. | PHARMACEUTICAL COMPOSITION COMPRISING A RECOMMENDED ADENO-ASSOCIATED VIRUS (AAV) VECTOR WITH AN EXPRESSION CASSETTE ENCODED BY A TRANSGENE FOR SUPRACHOROID ADMINISTRATION |
| TW202345913A (zh) | 2022-04-06 | 2023-12-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如凝膠調配物 |
| TW202404651A (zh) | 2022-04-06 | 2024-02-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如形成聚集體之調配物 |
| EP4593955A1 (en) | 2022-09-30 | 2025-08-06 | RegenxBio Inc. | Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2388432A1 (en) * | 1999-10-21 | 2001-04-26 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
| CN1461342A (zh) * | 2000-07-26 | 2003-12-10 | 路德维格癌症研究所 | 糖基化vegf－b和增加可溶性vegf－b量的方法 |
| BRPI1012321A8 (pt) * | 2009-06-17 | 2016-09-27 | Abbott Biotherapeutics Corp | Anticorpos anti-vegf e seus usos |
| US20130090375A1 (en) * | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| MY186389A (en) * | 2014-05-13 | 2021-07-22 | Univ Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
-
2017
- 2017-04-14 SG SG11201808440YA patent/SG11201808440YA/en unknown
- 2017-04-14 SG SG10202008378UA patent/SG10202008378UA/en unknown
- 2017-04-14 AU AU2017250797A patent/AU2017250797A1/en not_active Abandoned
- 2017-04-14 CA CA3019665A patent/CA3019665A1/en active Pending
- 2017-04-14 JP JP2019505138A patent/JP2019515027A/ja active Pending
- 2017-04-14 EP EP17783242.5A patent/EP3442577A4/en active Pending
- 2017-04-14 KR KR1020237043995A patent/KR20240005973A/ko active Pending
- 2017-04-14 US US16/093,363 patent/US20190127455A1/en not_active Abandoned
- 2017-04-14 WO PCT/US2017/027650 patent/WO2017181021A1/en not_active Ceased
- 2017-04-14 KR KR1020187032191A patent/KR20190003556A/ko not_active Ceased
-
2018
- 2018-10-10 IL IL262277A patent/IL262277A/en unknown
-
2019
- 2019-03-22 US US16/361,884 patent/US20190211091A1/en not_active Abandoned
-
2022
- 2022-03-25 US US17/704,170 patent/US20230057519A1/en not_active Abandoned
- 2022-07-06 JP JP2022108815A patent/JP2022153418A/ja active Pending
-
2024
- 2024-08-09 AU AU2024205641A patent/AU2024205641A1/en active Pending
- 2024-09-05 JP JP2024152809A patent/JP2025000642A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025000642A5 (OSRAM) | ||
| JP2024016207A5 (OSRAM) | ||
| JP2021516671A5 (OSRAM) | ||
| JP7421338B2 (ja) | 免疫調節融合タンパク質 | |
| JP2022521851A5 (OSRAM) | ||
| JP6355032B2 (ja) | 新規組換え二機能性融合タンパク質、それらの調製および使用 | |
| US20220096596A1 (en) | Method of treating amd in patients refractory to anti-vegf therapy | |
| CN117467025B (zh) | 一种抗vegf和补体双功能融合蛋白及其应用 | |
| JP2022552262A5 (OSRAM) | ||
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| JP2022545967A5 (OSRAM) | ||
| RU2018142768A (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| CN104023748A (zh) | 含有氨基酸的蛋白质制剂 | |
| US20140221295A1 (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| EP4549459A1 (en) | Aav drug for treating angiogenesis-related fundus diseases | |
| JP2023545424A5 (OSRAM) | ||
| ES2828694T3 (es) | Anticuerpos sólo de cadena pesada frente a ANG-2 | |
| US20220033476A1 (en) | Fusion protein of mutated single-chain human coagulation factor viii, preparation method therefor, and use thereof | |
| CN102690354B (zh) | 重组二聚化抗凝血酶III-Fc融合蛋白及其哺乳动物细胞高效表达系统 | |
| WO2019219049A1 (zh) | 改进的fviii融合蛋白及其应用 | |
| WO2018091621A1 (en) | Methods and pharmaceutical compositions for increasing endogenous protein level | |
| JP2025526875A (ja) | 改善された抗アルブミンナノボディおよびその使用 | |
| US20240285800A1 (en) | Retinal Disorders | |
| TW202530256A (zh) | 多特異性抗原結合多肽之組合物及使用方法 | |
| EP4703378A1 (en) | Drug for relieving ocular angiogenesis related diseases and use thereof |